[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "857-209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 23, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 63, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2020, "totalPay": 612000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 57, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2020, "totalPay": 589000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian  Piekos", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  DiVecchia", "title": "Senior Vice President of Operations & Human Resources", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1986, "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "John J. Concannon III", "title": "Secretary", "fiscalYear": 2020, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1704067200, "compensationAsOfEpochDate": 1609372800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.4, "open": 5.44, "dayLow": 5.06, "dayHigh": 5.44, "regularMarketPreviousClose": 5.4, "regularMarketOpen": 5.44, "regularMarketDayLow": 5.06, "regularMarketDayHigh": 5.44, "forwardPE": -1.7293729, "volume": 74571, "regularMarketVolume": 74571, "averageVolume": 79011, "averageVolume10days": 399640, "averageDailyVolume10Day": 399640, "bid": 5.17, "ask": 5.41, "bidSize": 900, "askSize": 1400, "marketCap": 50333604, "fiftyTwoWeekLow": 4.6, "fiftyTwoWeekHigh": 24.39, "fiftyDayAverage": 6.2983, "twoHundredDayAverage": 8.25772, "currency": "USD", "enterpriseValue": 36002612, "floatShares": 3620792, "sharesOutstanding": 9605650, "sharesShort": 6777, "sharesShortPriorMonth": 25439, "sharesShortPreviousMonthDate": 1701302400, "dateShortInterest": 1703808000, "sharesPercentSharesOut": 0.0011999999, "heldPercentInsiders": 0.42133, "heldPercentInstitutions": 0.0654, "shortRatio": 0.39, "impliedSharesOutstanding": 9605650, "bookValue": 1.586, "priceToBook": 3.303909, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -32895688, "trailingEps": -3.93, "forwardEps": -3.03, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -1.129, "52WeekChange": -0.2567376, "SandP52WeekChange": 0.19866347, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ELTX", "underlyingSymbol": "ELTX", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "firstTradeDateEpochUtc": 1612535400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "f5a7063e-a200-3645-afdf-a5955dd38a4c", "messageBoardId": "finmb_214936128", "gmtOffSetMilliseconds": -18000000, "currentPrice": 5.24, "targetHighPrice": 12.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.0, "targetMedianPrice": 12.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 14115000, "totalCashPerShare": 1.685, "ebitda": -31902436, "totalDebt": 6215000, "quickRatio": 1.229, "currentRatio": 1.735, "debtToEquity": 46.779, "returnOnAssets": -0.81482005, "financialCurrency": "USD", "trailingPegRatio": null}]